Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 4
Submit an article Journal homepage
3,387
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison

Stephen J. Schustera Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Jie Zhangb Novartis Pharmaceuticals, East Hanover, NJ, USAView further author information
,
Hongbo Yangc Analysis Group, Inc., Boston, MA, USAView further author information
,
Abhijit Agarwalb Novartis Pharmaceuticals, East Hanover, NJ, USAView further author information
,
Wenxi Tangc Analysis Group, Inc., Boston, MA, USAView further author information
,
Marcela Martinez-Prietob Novartis Pharmaceuticals, East Hanover, NJ, USAView further author information
,
Vamsi Bollub Novartis Pharmaceuticals, East Hanover, NJ, USAView further author information
,
David Kuzanb Novartis Pharmaceuticals, East Hanover, NJ, USAView further author information
,
Richard T. Maziarzd Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USACorrespondence[email protected]
View further author information
&
Marie José Kerstene Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, Netherlands, on behalf of HOVON/LLPC and LYMMCAREORCID Iconhttps://orcid.org/0000-0002-8904-3802View further author information
ORCID Icon show all
Pages 845-854 | Received 02 Nov 2021, Accepted 19 Nov 2021, Published online: 02 Jan 2022

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Razan Mohty, Yenny Moreno Vanegas, Julio C. Chavez & Mohamed A. Kharfan-Dabaja. (2023) Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma. Expert Review of Anticancer Therapy 23:2, pages 121-126.
Read now
Olalekan O. Oluwole, Rongzhe Liu, Ibrahim Diakite, Chaoling Feng, Anik Patel, Iman Nourhussein, Julia Thornton Snider & Frederick L. Locke. (2022) Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. Journal of Medical Economics 25:1, pages 541-551.
Read now

Articles from other publishers (4)

Paolo Strati, Tara Gregory, Navneet S. Majhail & Nitin Jain. (2023) Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review. JCO Oncology Practice 19:9, pages 706-713.
Crossref
Simon R. Mucha & Prabalini Rajendram. (2023) Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications. Current Oncology 30:5, pages 5003-5023.
Crossref
Semira Sheikh, Denis Migliorini & Noémie Lang. (2022) CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives. Biomedicines 10:8, pages 1960.
Crossref
Paolo Strati. (2022) CAR T-cell therapy: which product for which patient?. Blood 139:26, pages 3673-3674.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.